Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) have been given an average rating of “Hold” by the nine brokerages that are currently covering the company, Marketbeat reports. Three analysts have rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $11.80.
A number of analysts have issued reports on the company. Northland Securities reissued a “buy” rating on shares of Ironwood Pharmaceuticals in a research report on Monday, August 3rd. Morgan Stanley raised their target price on Ironwood Pharmaceuticals from $10.00 to $11.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Credit Suisse Group decreased their target price on Ironwood Pharmaceuticals from $12.00 to $11.00 and set a “neutral” rating for the company in a research report on Monday, June 1st. BidaskClub raised Ironwood Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday. Finally, ValuEngine lowered Ironwood Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, August 7th.
In related news, Director Julie Mchugh sold 7,950 shares of Ironwood Pharmaceuticals stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $9.77, for a total transaction of $77,671.50. Following the completion of the sale, the director now owns 123,107 shares of the company’s stock, valued at $1,202,755.39. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 2.40% of the stock is currently owned by company insiders.
Shares of IRWD opened at $10.15 on Wednesday. The company has a market capitalization of $1.62 billion, a price-to-earnings ratio of 16.64 and a beta of 1.47. The stock has a 50 day moving average of $9.95 and a 200 day moving average of $10.21. Ironwood Pharmaceuticals has a 12 month low of $7.91 and a 12 month high of $14.10.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.16 EPS for the quarter, beating the Zacks’ consensus estimate of $0.08 by $0.08. Ironwood Pharmaceuticals had a negative return on equity of 160.69% and a net margin of 22.74%. The company had revenue of $89.43 million during the quarter, compared to the consensus estimate of $85.38 million. During the same period last year, the business posted $0.10 earnings per share. Ironwood Pharmaceuticals’s revenue was down 12.5% on a year-over-year basis. Sell-side analysts anticipate that Ironwood Pharmaceuticals will post 0.51 EPS for the current year.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD.
Read More: What is Compound Annual Growth Rate (CAGR)?
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.